WalterJohnUrbaMDPhD

Oncology • Portland, OR

Hematologic Oncology, Melanoma

Director, Earle. A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon

Join to view full profile

Dr. Urba is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Urba's full profile

Already have an account?

Office
4805 Ne Glisan St
6n40
Portland, OR 97213
Phone+1 503-215-5696

Fax+1 503-215-5695

Summary

Dr. Walter Urba is an oncologist in Portland, OR and is affiliated with Providence Portland Medical Center. He received his Ph.D. in Immunology from UCLA and his medical degree from University of Miami Miller School of Medicine. He completed his medical oncology fellowship at the NCI. He specializes in medical oncology with expertise in immuno-oncology. He is director of the Robert W. Franz Cancer Center, Earle A. Chiles Research Institute and physician director of research for Providence in Oregon.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
Atlantic Health System/Morristown Medical CenterResidency, Internal Medicine, 1981 - 1983
University of Miami Leonard M. Miller School of MedicineClass of 1981

Certifications & Licensure

NJ State Medical License 1982 - Present
OR State Medical License 1993 - 2025
MD State Medical License 1984 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Portland Monthly Magazine Castle Connolly, 2011
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Vaccine Therapy in Treating Women With Metastatic Breast Cancer Start of enrollment: 1996 Aug 01
Completed
Phase 1
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2004 Jul 01
Completed
Phase 1
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01
Completed
Phase 1
Long-term Data Collection for Subjects in MDX-010 Studies Start of enrollment: 2007 Jun 01
Completed
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Start of enrollment: 2010 May 01
Active, not recruiting
Phase 1
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
Completed
Phase 1
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 2
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Start of enrollment: 2012 Apr 27
Completed
Phase 1
Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08
Completed
Phase 1
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery Start of enrollment: 2002 Oct 01
Completed
Phase 1
Immunoscore in Rectal Cancer Start of enrollment: 2014 Jan 24
Completed
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2014 May 08
Completed
Phase 1
α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04
Completed
Phase 1
Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24
Completed
Phase 1
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma Start of enrollment: 2016 Apr 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

355 citations
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D. Curti, Magdalena Kovacsovics-Bankowski, Nicholas P. Morris, Edwin B. Walker, Lana Chisholm
Cancer Research. 2013-12-15
10975 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi, Steven J. O'Day, David F. McDermott, R. W. Weber, Jeffrey A. Sosman
The New England Journal of Medicine. 2010-08-18
618 citations
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Alison M. Taylor, Juliann Shih, Gavin Ha, Galen F. Gao, Xiaoyang Zhang
Cancer Cell. 2018-04-09

Journal Articles

The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory Response
Steven J O'Day, Walter J Urba, Jeffrey S Weber, Journal For Immunotherapy of Cancer

Press Mentions

Germinal Center Reactions in Tertiary Lymphoid Structures Associate with Neoantigen Burden, Humoral Immunity and Long-Term Survivorship in Pancreatic CancerMarch 17th, 2021
Germinal Center Reactions in Tertiary Lymphoid Structures Associate with Neoantigen Burden, Humoral Immunity and Long-Term Survivorship in Pancreatic CancerDecember 8th, 2020
Providence Researchers Developing Unique COVID-19 VaccineJuly 11th, 2020
Join now to see all

Grant Support

Clinical Trial Of Dribble Vaccine In NsclcNational Cancer Institute2008–2009
Peptide Booster Vaccination In A2+ Melanoma PatientsNational Cancer Institute2004–2005
GP100 Peptide Immunization After Lymphocyte DepletionNational Cancer Institute2003–2004
Immune Response To The Mutated Gp?00 Peptide (209o-2m)National Cancer Institute2000
Immune Response To The Mutated GP 100 Peptide (209o 2m)National Cancer Institute1999
Vaccination With B7-Transfected Breast Cancer CellsNational Cancer Institute1996–1997